{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T18:15:14Z","timestamp":1788372914999,"version":"build-2803163510"},"reference-count":148,"publisher":"Informa UK Limited","issue":"16","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1080\/14656566.2024.2418986","type":"journal-article","created":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T05:37:01Z","timestamp":1729229821000},"page":"2177-2190","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":8,"title":["An update on the pharmacological management of acne vulgaris: the state of the art"],"prefix":"10.1080","volume":"25","author":[{"given":"Isabel Cristina","family":"Valente Duarte de Sousa","sequence":"first","affiliation":[{"name":"Department of Dermatology, Centro Medico ABC, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,10,20]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.17633"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.09.078"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-62715-3"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13675"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15862"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-020-00531-1"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2020.00450"},{"issue":"12","key":"e_1_3_4_10_1","first-page":"892","article-title":"Acne in adolescents","volume":"46","author":"Gebauer K","year":"2017","unstructured":"Gebauer K. Acne in adolescents. Aust Fam Physician. 2017;46(12):892\u2013895.","journal-title":"Aust Fam Physician"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.12.037"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13776"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.12708"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijd.IJD_671_16"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.2185"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2016.5538"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13548"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.12.017"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13186"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15843"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.10.879"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2007.02190.x"},{"issue":"2","key":"e_1_3_4_23_1","first-page":"145","article-title":"The efficacy and safety of adapalene gel 0.3% in the treatment of acne vulgaris: a randomized, multicenter, investigator-blinded, controlled comparison study versus adapalene gel 0.1% and vehicle","volume":"76","author":"Pariser DM","year":"2005","unstructured":"Pariser DM, Thiboutot DM, Clark SD, et al. The efficacy and safety of adapalene gel 0.3% in the treatment of acne vulgaris: a randomized, multicenter, investigator-blinded, controlled comparison study versus adapalene gel 0.1% and vehicle. Cutis. 2005;76(2):145\u2013151.","journal-title":"Cutis"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.2020.3977"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S34054"},{"issue":"10","key":"e_1_3_4_26_1","first-page":"1084","article-title":"Novel tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris: assessment of efficacy and safety in patients aged 9 years and older","volume":"17","author":"Tyring SK","year":"2018","unstructured":"Tyring SK, Kircik LH, Pariser DM, et al. Novel tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris: assessment of efficacy and safety in patients aged 9 years and older. J Drugs Dermatol. 2018;17(10):1084\u20131091.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2019.1587884"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1992.tb00196.x"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1177\/12034754231163542"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.02.044"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16719"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-017-0185-2"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-019-00423-z"},{"issue":"11","key":"e_1_3_4_34_1","first-page":"22","article-title":"Tretinoin: a review of its anti-inflammatory properties in the treatment of acne","volume":"4","author":"Schmidt N","year":"2011","unstructured":"Schmidt N, Eh G. Tretinoin: a review of its anti-inflammatory properties in the treatment of acne. J Clin Aesthet Dermatol. 2011;4(11):22\u201329.","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2017.1309349"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0190-9622(96)90443-0"},{"issue":"6","key":"e_1_3_4_37_1","first-page":"4","article-title":"Efficacy and tolerability of once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.025% gel in the treatment of facial acne vulgaris: a randomized trial","volume":"67","author":"Webster GF","year":"2001","unstructured":"Webster GF, Berson D, Stein LF, et al. Efficacy and tolerability of once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.025% gel in the treatment of facial acne vulgaris: a randomized trial. Cutis. 2001;67(6 Suppl):4\u20139.","journal-title":"Cutis"},{"issue":"2","key":"e_1_3_4_38_1","first-page":"4","article-title":"A multicenter, double-blind, randomized comparison study of the efficacy and tolerability of once-daily tazarotene 0.1% gel and adapalene 0.1% gel for the treatment of facial acne vulgaris","volume":"69","author":"Webster GF","year":"2002","unstructured":"Webster GF, Guenther L, Poulin YP, et al. A multicenter, double-blind, randomized comparison study of the efficacy and tolerability of once-daily tazarotene 0.1% gel and adapalene 0.1% gel for the treatment of facial acne vulgaris. Cutis. 2002;69(2 Suppl):4\u201311.","journal-title":"Cutis"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1177\/1203475415591117"},{"issue":"12","key":"e_1_3_4_40_1","first-page":"205","article-title":"Truncal acne: a neglected entity","volume":"18","author":"Del Rosso JQ","year":"2019","unstructured":"Del Rosso JQ, Stein-Gold L, Lynde C, et al. Truncal acne: a neglected entity. J Drugs Dermatol. 2019;18(12):205\u20131208.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16634"},{"issue":"12","key":"e_1_3_4_42_1","first-page":"1427","article-title":"Customized single-agent therapy management of severe inflammatory acne: a randomized, double-blind, parallel-group, controlled study of a new treatment- adapalene 0.3%-benzoyl peroxide 2.5% gel","volume":"14","author":"Weiss J","year":"2015","unstructured":"Weiss J, Stein Gold L, Leoni M, et al. Customized single-agent therapy management of severe inflammatory acne: a randomized, double-blind, parallel-group, controlled study of a new treatment- adapalene 0.3%-benzoyl peroxide 2.5% gel. J Drugs Dermatol. 2015;14(12):1427\u20131435.","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"e_1_3_4_43_1","first-page":"343","article-title":"Microencapsulated benzoyl peroxide and tretinoin for the treatment of acne vulgaris: results from a phase 2 multicenter, double-blind, randomized, vehicle-controlled study","volume":"18","author":"Webster GF","year":"2020","unstructured":"Webster GF, Sugarman J, Levy-Hacham O, et al. Microencapsulated benzoyl peroxide and tretinoin for the treatment of acne vulgaris: results from a phase 2 multicenter, double-blind, randomized, vehicle-controlled study. Skinmed. 2020;18(6):343\u2013351.","journal-title":"Skinmed"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.13497"},{"issue":"3","key":"e_1_3_4_45_1","first-page":"18","article-title":"Moisturizers and ceramide-containing moisturizers may offer concomitant therapy with benefits","volume":"7","author":"Lynde CW","year":"2014","unstructured":"Lynde CW, Andriessen A, Barankin B, et al. Moisturizers and ceramide-containing moisturizers may offer concomitant therapy with benefits. J Clin Aesthet Dermatol. 2014;7(3):18\u201326.","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00854-3"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.09.010"},{"key":"e_1_3_4_48_1","volume-title":"StatPearls [internet]","author":"Matin T","year":"2024","unstructured":"Matin T, Patel P, Goodman MB. Benzoyl peroxide. In: StatPearls [internet]. Treasure Island (FL): StatPearls Publishing; 2024. [accessed 2024 October 18]. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK537220\/"},{"issue":"10","key":"e_1_3_4_49_1","first-page":"5","article-title":"Benzoyl peroxide: enhancing antibiotic efficacy in acne management","volume":"15","author":"Dutil M","year":"2010","unstructured":"Dutil M. Benzoyl peroxide: enhancing antibiotic efficacy in acne management. Skin Therapy Lett. 2010;15(10):5\u20137.","journal-title":"Skin Therapy Lett"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.2165\/11597880-000000000-00000"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2008.07.001"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4362.1986.tb04534.x"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007997709110177"},{"issue":"4","key":"e_1_3_4_54_1","first-page":"548","article-title":"Retinoic acid cream (airol cream) and benzoyl-peroxide in the treatment of acne vulgaris","volume":"10","author":"Handojo I","year":"1979","unstructured":"Handojo I. Retinoic acid cream (airol cream) and benzoyl-peroxide in the treatment of acne vulgaris. Southeast Asian J Trop Med Public Health. 1979;10(4):548\u2013551.","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4362.1978.tb06072.x"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.06.006"},{"issue":"2","key":"e_1_3_4_57_1","first-page":"110","article-title":"A North American study of adapalene-benzoyl peroxide combination gel in the treatment of acne","volume":"84","author":"Gold LS","year":"2009","unstructured":"Gold LS, Tan J, Cruz-Santana A, et al. A North American study of adapalene-benzoyl peroxide combination gel in the treatment of acne. Cutis. 2009;84(2):110\u2013116.","journal-title":"Cutis"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09209.x"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1289\/EHP13984"},{"key":"e_1_3_4_60_1","unstructured":"Bader K. Updates on Benzene in Benzoyl Peroxide Products at AAD. Dermatology times. 2024 Mar 11 [cited 2019 Sep 12]. Available from: https:\/\/www.dermatologytimes.com\/view\/updates-on-benzene-in-benzoyl-peroxide-products-at-aad"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600660528"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1159\/000354888"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.5114\/ada.2023.133955"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.12889"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12823"},{"issue":"6","key":"e_1_3_4_66_1","first-page":"586","article-title":"Efficacy and safety of azelaic acid (AzA) gel 15% in the treatment of post-inflammatory hyperpigmentation and acne: a 16-week, baseline-controlled study","volume":"10","author":"Kircik LH","year":"2011","unstructured":"Kircik LH. Efficacy and safety of azelaic acid (AzA) gel 15% in the treatment of post-inflammatory hyperpigmentation and acne: a 16-week, baseline-controlled study. J Drugs Dermatol. 2011;10(6):586\u2013590.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12061"},{"issue":"1","key":"e_1_3_4_68_1","first-page":"s11","article-title":"Inflammatory acne treatment: review of current and new topical therapeutic options","volume":"15","author":"Zeichner JA","year":"2016","unstructured":"Zeichner JA. Inflammatory acne treatment: review of current and new topical therapeutic options. J Drugs Dermatol. 2016;15(1 Suppl 1):s11\u20136.","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"e_1_3_4_69_1","first-page":"556","article-title":"Treatment of mild and moderate acne vulgaris with salicylic acid in an alcohol-detergent vehicle","volume":"28","author":"Shalita AR","year":"1981","unstructured":"Shalita AR. Treatment of mild and moderate acne vulgaris with salicylic acid in an alcohol-detergent vehicle. Cutis. 1981;28(5):556\u2013558.","journal-title":"Cutis"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06614.x"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8019.2012.01493.x"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.05.078"},{"issue":"11","key":"e_1_3_4_73_1","first-page":"25","article-title":"BPX-01\u00a0minocycline topical gel shows promise for the treatment of moderate-to-severe inflammatory acne vulgaris","volume":"11","author":"Alexis A","year":"2018","unstructured":"Alexis A, Del Rosso J, Desai S, et al. BPX-01\u00a0minocycline topical gel shows promise for the treatment of moderate-to-severe inflammatory acne vulgaris. J Clin Aesthet Dermatol. 2018;11(11):25\u201335.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"12","key":"e_1_3_4_74_1","first-page":"1382","article-title":"Safety and efficacy of clindamycin phosphate 1.2%-benzoyl peroxide 3% fixed-dose combination gel for the treatment of acne vulgaris: a phase 3, multicenter, randomized, double-blind, active- and vehicle-controlled study","volume":"10","author":"Eichenfield LF","year":"2011","unstructured":"Eichenfield LF, Alio Saenz AB. Safety and efficacy of clindamycin phosphate 1.2%-benzoyl peroxide 3% fixed-dose combination gel for the treatment of acne vulgaris: a phase 3, multicenter, randomized, double-blind, active- and vehicle-controlled study. J Drugs Dermatol. 2011;10(12):1382\u20131396.","journal-title":"J Drugs Dermatol"},{"issue":"8","key":"e_1_3_4_75_1","first-page":"962","article-title":"Efficacy and safety of once-daily dapsone gel, 7.5% for treatment of adolescents and adults with acne vulgaris: second of two identically designed, large, multicenter, randomized, vehicle-controlled trials","volume":"15","author":"Eichenfield LF","year":"2016","unstructured":"Eichenfield LF, Lain T, Frankel EH, et al. Efficacy and safety of once-daily dapsone gel, 7.5% for treatment of adolescents and adults with acne vulgaris: second of two identically designed, large, multicenter, randomized, vehicle-controlled trials. J Drugs Dermatol. 2016;15(8):962\u2013969.","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"e_1_3_4_76_1","first-page":"553","article-title":"Efficacy and safety of once-daily dapsone gel, 7.5% for treatment of adolescents and adults with acne vulgaris: first of two identically designed, large, multicenter, randomized, vehicle-controlled trials","volume":"15","author":"Stein Gold LF","year":"2016","unstructured":"Stein Gold LF, Jarratt MT, Bucko AD, et al. Efficacy and safety of once-daily dapsone gel, 7.5% for treatment of adolescents and adults with acne vulgaris: first of two identically designed, large, multicenter, randomized, vehicle-controlled trials. J Drugs Dermatol. 2016;15(5):553\u2013561.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2014.2309"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.6.3.409"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-020-00523-1"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anaerobe.2020.102169"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.08.020"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-013-1409-7"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-016-0242-0"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.10.005"},{"issue":"5","key":"e_1_3_4_85_1","doi-asserted-by":"crossref","first-page":"AB2","DOI":"10.1016\/j.jaad.2016.02.007","article-title":"Age and gender as predictors of treatment outcomes with once-daily dapsone 7.5% topical gel for acne vulgaris (abstract no. 3244 plus poster)","volume":"74","author":"Draelos ZD","year":"2016","unstructured":"Draelos ZD, Rodriguez DA, Kempers SE, et al. Age and gender as predictors of treatment outcomes with once-daily dapsone 7.5% topical gel for acne vulgaris (abstract no. 3244 plus poster). J Am Acad Dermatol. 2016 [cited 2024 Sep 16];74(5 Suppl 1):AB2. https:\/\/www.em-consulte.com\/es\/article\/1049482\/age-and-gender-as-predictors-of-treatment-outcomes","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"e_1_3_4_86_1","first-page":"45","article-title":"Management of truncal acne vulgaris with topical dapsone 7.5% gel","volume":"11","author":"Del Rosso JQ","year":"2018","unstructured":"Del Rosso JQ, Kircik L, Tanghetti E. Management of truncal acne vulgaris with topical dapsone 7.5% gel. J Clin Aesthet Dermatol. 2018;11(8):45\u201350.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"12","key":"e_1_3_4_87_1","first-page":"1331","article-title":"A call to limit antibiotic use in acne","volume":"12","author":"Thiboutot D","year":"2013","unstructured":"Thiboutot D, Dreno B, Gollnick H, et al. A call to limit antibiotic use in acne. J Drugs Dermatol. 2013;12(12):1331\u20131332.","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"e_1_3_4_88_1","first-page":"391","article-title":"European recommendations on the use of oral antibiotics for acne","volume":"14","author":"Dreno B","year":"2004","unstructured":"Dreno B, Bettoli V, Ochsendorf F, et al. European recommendations on the use of oral antibiotics for acne. Eur J Dermatol. 2004;14(6):391\u2013399.","journal-title":"Eur J Dermatol"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00527-7"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S114830"},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2005.07.010"},{"key":"e_1_3_4_92_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-016-0245-x"},{"key":"e_1_3_4_93_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14609"},{"issue":"3","key":"e_1_3_4_94_1","first-page":"30","article-title":"Androgens, androgen receptors, and the skin: from the laboratory to the clinic with emphasis on clinical and Therapeutic implications","volume":"19","author":"Del Rosso JQ","year":"2020","unstructured":"Del Rosso JQ, Kircik LH, Stein Gold L, et al. Androgens, androgen receptors, and the skin: from the laboratory to the clinic with emphasis on clinical and Therapeutic implications. J Drugs Dermatol. 2020;19(3):30\u201335.","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"e_1_3_4_95_1","first-page":"412","article-title":"Cortexolone 17\u03b1-propionate (clascoterone) is a novel androgen receptor antagonist that inhibits production of lipids and inflammatory cytokines from sebocytes in vitro","volume":"18","author":"Rosette C","year":"2019","unstructured":"Rosette C, Agan FJ, Mazzetti A, et al. Cortexolone 17\u03b1-propionate (clascoterone) is a novel androgen receptor antagonist that inhibits production of lipids and inflammatory cytokines from sebocytes in vitro. J Drugs Dermatol. 2019;18(5):412\u2013418.","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"e_1_3_4_96_1","first-page":"1","article-title":"Topical clascoterone for acne vulgaris","volume":"27","author":"Burma NE","year":"2022","unstructured":"Burma NE, Woo TE, Parsons L. Topical clascoterone for acne vulgaris. Skin Therapy Lett. 2022;27(1):1\u20133.","journal-title":"Skin Therapy Lett"},{"key":"e_1_3_4_97_1","doi-asserted-by":"publisher","DOI":"10.1039\/c4md00049h"},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200102010-00006"},{"key":"e_1_3_4_99_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546631003681094"},{"issue":"2","key":"e_1_3_4_100_1","first-page":"103","article-title":"Simplifying regimens promotes greater adherence and outcomes with topical acne medications: a randomized controlled trial","volume":"86","author":"Yentzer BA","year":"2010","unstructured":"Yentzer BA, Ade RA, Fountain JM, et al. Simplifying regimens promotes greater adherence and outcomes with topical acne medications: a randomized controlled trial. Cutis. 2010;86(2):103\u2013108.","journal-title":"Cutis"},{"key":"e_1_3_4_101_1","volume-title":"Bausch health companies inc","author":"FDA approves Cabtreo (clindamycin phosphate, adapalene and benzoyl peroxide) topical gel for the treatment of acne vulgaris in patients twelve years of age and older","year":"2023","unstructured":"FDA approves Cabtreo (clindamycin phosphate, adapalene and benzoyl peroxide) topical gel for the treatment of acne vulgaris in patients twelve years of age and older. Bausch health companies inc. 2023 Oct 20 [cited 2024 Jun 24]. Available from: https:\/\/ir.bauschhealth.com\/news-releases\/2023\/10-20-2023"},{"key":"e_1_3_4_102_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00650-3"},{"key":"e_1_3_4_103_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12370"},{"key":"e_1_3_4_104_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-017-0267-z"},{"key":"e_1_3_4_105_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.12075"},{"key":"e_1_3_4_106_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2020.1813279"},{"key":"e_1_3_4_107_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01297-18"},{"key":"e_1_3_4_108_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-020-00560-w"},{"key":"e_1_3_4_109_1","doi-asserted-by":"publisher","DOI":"10.4103\/CDR_2_17"},{"key":"e_1_3_4_110_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2013.10.003"},{"key":"e_1_3_4_111_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijwd.2018.03.006"},{"key":"e_1_3_4_112_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2016.09.007"},{"key":"e_1_3_4_113_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.4944"},{"key":"e_1_3_4_114_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2022.2102605"},{"key":"e_1_3_4_115_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.247.13.1800"},{"key":"e_1_3_4_116_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.abd.2020.09.001"},{"key":"e_1_3_4_117_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15974"},{"key":"e_1_3_4_118_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-0960.2012.00947.x"},{"key":"e_1_3_4_119_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14438"},{"key":"e_1_3_4_120_1","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2008.0441"},{"issue":"9","key":"e_1_3_4_121_1","first-page":"20","article-title":"Rationale for use of micronized isotretinoin for treatment of acne vulgaris: practical considerations and therapeutic advantages","volume":"16","author":"Del Rosso JQ","year":"2023","unstructured":"Del Rosso JQ. Rationale for use of micronized isotretinoin for treatment of acne vulgaris: practical considerations and therapeutic advantages. J Clin Aesthet Dermatol. 2023 Sep;16(9):20\u201324.","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_3_4_122_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.05.036"},{"issue":"11","key":"e_1_3_4_123_1","first-page":"13","article-title":"An open-label, phase IV study evaluating lidose-isotretinoin administered without food in patients with severe recalcitrant nodular acne: low relapse rates observed over the 104-week post-treatment period","volume":"12","author":"Del Rosso JQ","year":"2019","unstructured":"Del Rosso JQ, Stein Gold L, Segal J, et al. An open-label, phase IV study evaluating lidose-isotretinoin administered without food in patients with severe recalcitrant nodular acne: low relapse rates observed over the 104-week post-treatment period. J Clin Aesthet Dermatol. 2019;12(11):13\u201318.","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_3_4_124_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3381"},{"key":"e_1_3_4_125_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.3091"},{"key":"e_1_3_4_126_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.2044"},{"key":"e_1_3_4_127_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009435.pub2"},{"key":"e_1_3_4_128_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.1416"},{"key":"e_1_3_4_129_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.01.107"},{"key":"e_1_3_4_130_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.12.028"},{"key":"e_1_3_4_131_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-021549"},{"key":"e_1_3_4_132_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sder.2005.04.003"},{"key":"e_1_3_4_133_1","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llae168"},{"key":"e_1_3_4_134_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13191"},{"issue":"1","key":"e_1_3_4_135_1","first-page":"37","article-title":"Fixed-dose combination gel of Adapalene and benzoyl peroxide plus doxycycline 100 mg versus oral isotretinoin for the treatment of severe acne: efficacy and cost analysis","volume":"7","author":"Penna P","year":"2014","unstructured":"Penna P, Meckfessel MH, Preston N. Fixed-dose combination gel of Adapalene and benzoyl peroxide plus doxycycline 100 mg versus oral isotretinoin for the treatment of severe acne: efficacy and cost analysis. Am Health Drug Benefits. 2014;7(1):37\u201345.","journal-title":"Am Health Drug Benefits"},{"key":"e_1_3_4_136_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sder.2008.06.001"},{"issue":"12","key":"e_1_3_4_138_1","first-page":"1496","article-title":"Results of a phase 2, randomized, vehicle-controlled study evaluating the efficacy, toler- ability, and safety of daily or twice daily SB204 for the treatment of acne vulgaris","volume":"15","author":"Eichenfield LF","year":"2016","unstructured":"Eichenfield LF, Gold WK, Cook-Bolden FE, et al. Results of a phase 2, randomized, vehicle-controlled study evaluating the efficacy, toler- ability, and safety of daily or twice daily SB204 for the treatment of acne vulgaris. J Drugs Dermatol. 2016;15(12):1496\u201315027.","journal-title":"J Drugs Dermatol"},{"issue":"8","key":"e_1_3_4_139_1","first-page":"12","article-title":"Results of a phase 2 efficacy and safety study with SB204, an investigational topical nitric oxide- releasing drug for the treatment of acne vulgaris","volume":"9","author":"Baldwin H","year":"2016","unstructured":"Baldwin H, Blanco D, McKeever C, et al. Results of a phase 2 efficacy and safety study with SB204, an investigational topical nitric oxide- releasing drug for the treatment of acne vulgaris. J Clin Aesthet Dermatol. 2016;9(8):12.","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_3_4_140_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2013.10.065"},{"key":"e_1_3_4_141_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-29580-7"},{"key":"e_1_3_4_142_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0000000000001053"},{"key":"e_1_3_4_143_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2009.02.006"},{"key":"e_1_3_4_144_1","unstructured":"Borunda JSA Castro JARM Santoyo PP et al. Semi-solid topical composition containing pirfenidone and modified diallyl disulfide oxide (M-DDO) for eliminating or preventing acne. National Library of Medicine. [cited 2024 Jun 24]. Available from: https:\/\/pubchem.ncbi.nlm.nih.gov\/patent\/US-11766426-B2"},{"key":"e_1_3_4_145_1","unstructured":"A multi-center double-blind vehicle-controlled study to evalu- ate the clinical effect of daily next scienceTM acne gel (NAG) on mild to moderate facial acne: identifier: NCT02404285 clinical trials: a service of the U.S national institutes of health. [cited 2024 Jun 24]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02404285"},{"key":"e_1_3_4_146_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2014.5254"},{"key":"e_1_3_4_147_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.0465"},{"key":"e_1_3_4_148_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13579"},{"key":"e_1_3_4_149_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14410"},{"key":"e_1_3_4_150_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12720"},{"key":"e_1_3_4_151_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12895-015-0036-8"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2024.2418986","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T07:04:20Z","timestamp":1731913460000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2024.2418986"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,20]]},"references-count":148,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1080\/14656566.2024.2418986"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2024.2418986","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,20]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-06-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}